[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note",
    "summary": "In the most recent trading session, Bristol Myers Squibb (BMY) closed at $44.16, indicating a -1.67% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=96e471a7cd3aad9425e2898f48d090d19191da809f5e5f5abc8ce48793fea7bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758750305,
      "headline": "Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note",
      "id": 136866239,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Bristol Myers Squibb (BMY) closed at $44.16, indicating a -1.67% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=96e471a7cd3aad9425e2898f48d090d19191da809f5e5f5abc8ce48793fea7bd"
    }
  },
  {
    "ts": null,
    "headline": "Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually",
    "summary": "Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=7ecb21fb8423fde87617c6680b90e9f8522d8dbd7307e733cd3cdfce246117e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758735634,
      "headline": "Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually",
      "id": 136865405,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1162606801/image_1162606801.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=7ecb21fb8423fde87617c6680b90e9f8522d8dbd7307e733cd3cdfce246117e3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a7735d7a650e00e22aba40815e7f5883be97892d551a6881c88a3547ceab6ab9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758732000,
      "headline": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
      "id": 136925589,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a7735d7a650e00e22aba40815e7f5883be97892d551a6881c88a3547ceab6ab9"
    }
  },
  {
    "ts": null,
    "headline": "REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug",
    "summary": "Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.",
    "url": "https://finnhub.io/api/news?id=124732d7a42bb3d25d1c28b710f0dd3775ebd14a2010524e2dcb01769bc877f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758726360,
      "headline": "REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug",
      "id": 136866240,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.",
      "url": "https://finnhub.io/api/news?id=124732d7a42bb3d25d1c28b710f0dd3775ebd14a2010524e2dcb01769bc877f7"
    }
  },
  {
    "ts": null,
    "headline": "BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study",
    "summary": "Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.",
    "url": "https://finnhub.io/api/news?id=6500c22c2454849e6aa970a1b76ae65bdc0d9901ef46e2bcf229c516f79774e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758721380,
      "headline": "BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study",
      "id": 136866241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.",
      "url": "https://finnhub.io/api/news?id=6500c22c2454849e6aa970a1b76ae65bdc0d9901ef46e2bcf229c516f79774e3"
    }
  },
  {
    "ts": null,
    "headline": "The Smartest Dividend Stock to Buy With $1,000 Right Now",
    "summary": "Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.",
    "url": "https://finnhub.io/api/news?id=ebc306ebeb1bb9c44e3e8327380a59c0d6187d4366d3fb09bafe16897e87e9d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758714300,
      "headline": "The Smartest Dividend Stock to Buy With $1,000 Right Now",
      "id": 136861679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.",
      "url": "https://finnhub.io/api/news?id=ebc306ebeb1bb9c44e3e8327380a59c0d6187d4366d3fb09bafe16897e87e9d4"
    }
  },
  {
    "ts": null,
    "headline": "SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform",
    "summary": "SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren (izalontamab brengitecan) and BL-M07D1, two distinct clinical programs from its antibody drug conjugate (ADC) pipeline, at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany. Iza-bren, a potentially first-in-class EGFRxHER3 bispecific ADC, is jointly developed by SystImmune and Bristol Myers Squibb under a collabora",
    "url": "https://finnhub.io/api/news?id=a08865704a05704b791db2d200c084f1d6c367c210181f734f567269bd91f55a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758711600,
      "headline": "SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform",
      "id": 136861885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren (izalontamab brengitecan) and BL-M07D1, two distinct clinical programs from its antibody drug conjugate (ADC) pipeline, at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany. Iza-bren, a potentially first-in-class EGFRxHER3 bispecific ADC, is jointly developed by SystImmune and Bristol Myers Squibb under a collabora",
      "url": "https://finnhub.io/api/news?id=a08865704a05704b791db2d200c084f1d6c367c210181f734f567269bd91f55a"
    }
  }
]